You appear to be using incognito/private browsing mode or an ad blocker, which may adversely affect your experience on the site. Please disable any ad blockers and view the site in non-private mode.
For in vitro diagnostic use. Others AMPS2 IVD AMPS2 CPS_000028 ONLINE DAT Amphetamines II 08056781190 AMPS2, 850T, cobas c pack green AMPS2 07613336120996 Reagents, kits 850 tests cobas c 303/503 true 06334385190 AMPS2, 100T, cobas c 701/702 AMPS2 04015630930302 Reagents, kits 100 tests cobas c 701/702 true 04512936190 AMPII, 200T, cobas Integra Amphetamines II 04015630997589 Reagents, kits 200 tests COBAS INTEGRA 400 Plus true 04939425190 AMPS2, 200T, cobas c AMPS2 04015630999194 Reagents, kits 200 tests cobas c 311/501/502 true 0108056781190c503 AMPS2 ONLINE DAT Amphetamines II en 5 FF00000004F2780E FF00000004DC820E 08056781190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Amphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on Roche/Hitachi cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0208056781190c503 AMPS2 ONLINE DAT Amphetamines II en 4 FF00000006DEA80E FF00000005BA000E 08056781190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 08056781500 AMPS2 ONLINE DAT Amphetamines II en 7 FF00000006F1590E FF00000004DC730E 08056781190 10299 cobas c 703 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.Application in serum and plasma**not available in all countriesAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative detection of amphetamines and methamphetamines in human serum and plasma on cobas c systems. For serum/plasma the cutoff concentration is 300 ng/mL when calibrated with d‑methamphetamine. Amphetamines II provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 06334385500 AMPS2 ONLINE DAT Amphetamines II en 9 FF00000007081D0E FF0000000058650E 06334385190 2492 cobas c 702 310 cobas c 701 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0204512936190COIN AMPII ONLINE DAT Amphetamines II en 7 FF00000005DC970E FF00000005DC960E 04512936190 302 COBAS INTEGRA 400 plus Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use Amphetamines II (AMPII) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on COBAS INTEGRA systems at cutoff concentrations of 300 ng/mL, 500 ng/mL and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC/MS).Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.Clinical consideration and professional judgement should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 04939425500 AMPS2 ONLINE DAT Amphetamines II en 14 FF00000006C7070E FF00000000562E0E 04939425190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. Application in serum and plasma**not available on all countriesAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative detection of amphetamines and methamphetamines in human serum and plasma on cobas c systems. For serum/plasma the cutoff concentration is 300 ng/mL when calibrated with d‑methamphetamine. Amphetamines II provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 1704939425190c501sp AMPS2 ONLINE DAT Amphetamines II en 4 FF0000000486CD0E FF00000001EEF90E 04939425190 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative detection of amphetamines and methamphetamines in human serum and plasma on Roche/Hitachi cobas c systems. For serum/plasma the cutoff concentration is 300 ng/mL when calibrated with d‑methamphetamine. Amphetamines II provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0204939425190c501 AMPS2 ONLINE DAT Amphetamines II en 14 FF000000070E4D0E FF000000070E4D0E 04939425190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 04939425500 AMPS2 ONLINE DAT Amphetamines II en 15 FF0000000708210E FF0000000030C50E 04939425190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useApplication in urineAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative and semiquantitative detection of amphetamines and methamphetamines in human urine on cobas c systems at cutoff concentrations of 300 ng/mL, 500 ng/mL, and 1000 ng/mL when calibrated with d‑methamphetamine. Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). Amphetamines II provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. Application in serum and plasma**not available on all countriesAmphetamines II (AMPS2) is an in vitro diagnostic test for the qualitative detection of amphetamines and methamphetamines in human serum and plasma on cobas c systems. For serum/plasma the cutoff concentration is 300 ng/mL when calibrated with d‑methamphetamine. Amphetamines II provides only a preliminary test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC‑MS) or Liquid Chromatography coupled with Tandem Mass Spectrometry (LC‑MS/MS) is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en